CPSF4 and Parkinson disease: This study aimed to investigate the therapeutic potential and mechanisms of NJ-1A and Nar in Parkinson’s disease by using two well-established models: an in vitro lipopolysaccharide (LPS)-induced microglial model, and an in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid (MPTP/p)-induced mouse chronic model of Parkinson’s disease.